HUTCHMED (China) Limited
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), b… Read more
HUTCHMED (China) Limited (HMDCF) - Net Assets
Latest net assets as of December 2025: $1.25 Billion USD
Based on the latest financial reports, HUTCHMED (China) Limited (HMDCF) has net assets worth $1.25 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.75 Billion) and total liabilities ($501.83 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.25 Billion |
| % of Total Assets | 71.37% |
| Annual Growth Rate | N/A |
| 5-Year Change | 20.35% |
| 10-Year Change | 513.1% |
| Growth Volatility | 47.39 |
HUTCHMED (China) Limited - Net Assets Trend (2005–2025)
This chart illustrates how HUTCHMED (China) Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for HUTCHMED (China) Limited (2005–2025)
The table below shows the annual net assets of HUTCHMED (China) Limited from 2005 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.25 Billion | +62.09% |
| 2024-12-31 | $771.85 Million | +3.83% |
| 2023-12-31 | $743.39 Million | +16.73% |
| 2022-12-31 | $636.87 Million | -38.73% |
| 2021-12-31 | $1.04 Billion | +100.31% |
| 2020-12-31 | $518.95 Million | +65.85% |
| 2019-12-31 | $312.90 Million | -24.10% |
| 2018-12-31 | $412.25 Million | -14.99% |
| 2017-12-31 | $484.97 Million | +137.66% |
| 2016-12-31 | $204.06 Million | +99.52% |
| 2015-12-31 | $102.28 Million | -14.69% |
| 2014-12-31 | $119.88 Million | +14.35% |
| 2013-12-31 | $104.84 Million | +25.33% |
| 2012-12-31 | $83.65 Million | +8.17% |
| 2011-12-31 | $77.33 Million | +12.39% |
| 2010-12-31 | $68.81 Million | -8.62% |
| 2009-12-31 | $75.30 Million | -10.81% |
| 2008-12-31 | $84.43 Million | -13.50% |
| 2007-12-31 | $97.61 Million | -11.25% |
| 2006-12-31 | $109.98 Million | +492.65% |
| 2005-12-31 | $-28.01 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to HUTCHMED (China) Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 34444865960.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $87.22 Million | 7.05% |
| Other Comprehensive Income | $-4.53 Million | -0.37% |
| Other Components | $1.53 Billion | 123.91% |
| Total Equity | $1.24 Billion | 100.00% |
HUTCHMED (China) Limited Competitors by Market Cap
The table below lists competitors of HUTCHMED (China) Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Quaker Chemical Corporation
NYSE:KWR
|
$1.63 Billion |
|
Hebei Yangyuan ZhiHui Beverage Co Ltd
SHG:603156
|
$1.63 Billion |
|
Inner Mongolia First Machinery Group Co Ltd
SHG:600967
|
$1.63 Billion |
|
Poco Holding Co Ltd
SHE:300811
|
$1.63 Billion |
|
Linktel Technologies Co. Ltd. A
SHE:301205
|
$1.63 Billion |
|
HEXPOL AB ser. B
LSE:0R7O
|
$1.63 Billion |
|
Calumet Specialty Products Partners
NASDAQ:CLMT
|
$1.63 Billion |
|
Manappuram Finance Limited
NSE:MANAPPURAM
|
$1.63 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HUTCHMED (China) Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 759,929,000 to 1,237,763,101, a change of 477,834,101 (62.9%).
- Net income of 457,584,900 contributed positively to equity growth.
- New share issuances of 1,578,000 increased equity.
- Other comprehensive income decreased equity by 4,531,403.
- Other factors increased equity by 23,202,604.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $457.58 Million | +36.97% |
| Share Issuances | $1.58 Million | +0.13% |
| Other Comprehensive Income | $-4.53 Million | -0.37% |
| Other Changes | $23.20 Million | +1.87% |
| Total Change | $- | 62.88% |
Book Value vs Market Value Analysis
This analysis compares HUTCHMED (China) Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.26x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | $-0.09 | $3.21 | x |
| 2006-12-31 | $0.23 | $3.21 | x |
| 2007-12-31 | $0.18 | $3.21 | x |
| 2008-12-31 | $0.15 | $3.21 | x |
| 2009-12-31 | $0.13 | $3.21 | x |
| 2010-12-31 | $0.12 | $3.21 | x |
| 2011-12-31 | $0.12 | $3.21 | x |
| 2012-12-31 | $0.13 | $3.21 | x |
| 2013-12-31 | $0.17 | $3.21 | x |
| 2014-12-31 | $0.18 | $3.21 | x |
| 2015-12-31 | $0.15 | $3.21 | x |
| 2016-12-31 | $0.31 | $3.21 | x |
| 2017-12-31 | $0.75 | $3.21 | x |
| 2018-12-31 | $0.59 | $3.21 | x |
| 2019-12-31 | $0.43 | $3.21 | x |
| 2020-12-31 | $0.69 | $3.21 | x |
| 2021-12-31 | $1.25 | $3.21 | x |
| 2022-12-31 | $0.72 | $3.21 | x |
| 2023-12-31 | $0.84 | $3.21 | x |
| 2024-12-31 | $0.87 | $3.21 | x |
| 2025-12-31 | $1.42 | $3.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently HUTCHMED (China) Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 36.97%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 83.30%
- • Asset Turnover: 0.31x
- • Equity Multiplier: 1.42x
- Recent ROE (36.97%) is above the historical average (-7.30%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 0.00% | -17.90% | 0.60x | 0.00x | $-3.41 Million |
| 2006 | -9.33% | -19.05% | 0.38x | 1.29x | $-19.90 Million |
| 2007 | -19.04% | -26.40% | 0.51x | 1.41x | $-26.22 Million |
| 2008 | -23.63% | -20.41% | 0.74x | 1.57x | $-25.27 Million |
| 2009 | -13.28% | -7.88% | 0.87x | 1.94x | $-15.34 Million |
| 2010 | -11.53% | -5.10% | 0.84x | 2.69x | $-12.82 Million |
| 2011 | 1.10% | 0.43% | 0.86x | 3.01x | $-5.77 Million |
| 2012 | 5.15% | 1.86% | 0.93x | 2.97x | $-3.42 Million |
| 2013 | 6.66% | 12.87% | 0.25x | 2.09x | $-2.97 Million |
| 2014 | 5.66% | 5.85% | 0.42x | 2.31x | $-4.11 Million |
| 2015 | 9.59% | 4.49% | 0.78x | 2.76x | $-342.60K |
| 2016 | 6.35% | 5.41% | 0.63x | 1.86x | $-6.73 Million |
| 2017 | -5.79% | -11.08% | 0.40x | 1.29x | $-72.91 Million |
| 2018 | -19.23% | -34.94% | 0.40x | 1.37x | $-113.70 Million |
| 2019 | -36.81% | -51.75% | 0.44x | 1.61x | $-134.83 Million |
| 2020 | -25.97% | -55.15% | 0.31x | 1.50x | $-174.14 Million |
| 2021 | -19.72% | -54.66% | 0.26x | 1.39x | $-293.34 Million |
| 2022 | -59.12% | -84.62% | 0.41x | 1.69x | $-421.87 Million |
| 2023 | 13.80% | 12.03% | 0.65x | 1.75x | $27.73 Million |
| 2024 | 4.96% | 5.99% | 0.49x | 1.68x | $-38.26 Million |
| 2025 | 36.97% | 83.30% | 0.31x | 1.42x | $333.81 Million |
Industry Comparison
This section compares HUTCHMED (China) Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| HUTCHMED (China) Limited (HMDCF) | $1.25 Billion | 0.00% | 0.40x | $1.63 Billion |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |